

Senate Bill 241

By: Senators Unterman of the 45th, Burke of the 11th, Miller of the 49th, Watson of the 1st and Hufstetler of the 52nd

**AS PASSED SENATE**

**A BILL TO BE ENTITLED**

**AN ACT**

1 To amend Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to  
2 controlled substances, so as to change certain provisions of the electronic data base of  
3 prescription information; to transfer responsibilities for the electronic data base of  
4 prescription information of the Georgia Drugs and Narcotics Agency to the Department of  
5 Public Health; to provide for the department's authority to continue the maintenance and  
6 development of the electronic data base of prescription information; to provide for  
7 definitions; to change the frequency of reporting provision; to amend Article 1 of Chapter 2A  
8 of Title 31 of the Official Code of Georgia Annotated, relating to the Department of Public  
9 Health, so as to provide for the department to maintain and administer the electronic data  
10 base of prescription information; to amend Article 9 of Chapter 7 of Title 31 of the Official  
11 Code of Georgia Annotated, relating to hospice care, so as to provide for the disposal of  
12 controlled substances upon the death of a hospice patient; to provide for a definition; to  
13 provide for persons authorized to dispose of controlled substances; to provide for a time  
14 frame; to provide for related matters; to repeal conflicting laws; and for other purposes.

15 **BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:**

16 **SECTION 1.**

17 Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled  
18 substances, is amended by adding new paragraphs to Code Section 16-13-21, relating to  
19 definitions, to read as follows:

20 "(6.3) 'De-identified' means data that has been processed to remove personal identifiers  
21 from the health information in compliance with the standard and implementation rules  
22 of the federal Health Insurance Portability and Accountability Act (HIPAA) of 1996,  
23 P.L. 104-191."

24 "(7.1) 'Department' means the Department of Public Health."

25 **SECTION 2.**

26 Said chapter is further amended by revising Code Section 16-13-57, relating to program to  
 27 record prescription information into electronic data base, administration, and oversight, as  
 28 follows:

29 "16-13-57.

30 (a) Subject to funds as may be appropriated by the General Assembly or otherwise  
 31 available for such purpose, the agency department shall, in consultation with members of  
 32 the Georgia Composite Medical Board, the State Board of Pharmacy, and the agency,  
 33 establish and maintain a program to electronically record into an electronic data base  
 34 prescription information resulting from the dispensing of Schedule II, III, IV, or V  
 35 controlled substances and to electronically review such prescription information that has  
 36 been entered into such data base. The purpose of such program shall be to assist in the  
 37 reduction of the abuse of controlled substances; to improve, enhance, and encourage a  
 38 better quality of health care by promoting the proper use of medications to treat pain and  
 39 terminal illness; and to reduce duplicative prescribing and overprescribing of controlled  
 40 substance practices; for health oversight purposes; and to gather data for epidemiological  
 41 research.

42 (b) Such program shall be administered by the ~~agency at the direction and oversight of the~~  
 43 ~~board~~ department."

44 **SECTION 3.**

45 Said chapter is further amended by revising Code Section 16-13-58, relating to funds for  
 46 development and maintenance of program and granting of funds to dispensers, as follows:

47 "16-13-58.

48 (a) The agency department shall be authorized to apply for available grants and may accept  
 49 any gifts, grants, donations, and other funds to assist in developing and maintaining the  
 50 program established pursuant to Code Section 16-13-57; provided, however, that neither  
 51 the ~~board, agency, department~~ nor any other state entity shall accept a grant that requires  
 52 as a condition of the grant any sharing of information that is inconsistent with this part.

53 (b) The agency department shall be authorized to grant funds to dispensers for the purpose  
 54 of covering costs for dedicated equipment and software for dispensers to use in complying  
 55 with the reporting requirements of Code Section 16-13-59. Such grants to dispensers shall  
 56 be funded by gifts, grants, donations, or other funds received by the agency department for  
 57 the operation of the program established pursuant to Code Section 16-13-57. The agency  
 58 department shall be authorized to establish standards and specifications for any equipment  
 59 and software purchased pursuant to a grant received by a dispenser pursuant to this Code

60 section. Nothing in this part shall be construed to require a dispenser to incur costs to  
 61 purchase equipment or software to comply with this part.

62 (c) Nothing in this part shall be construed to require any appropriation of state funds."

63 **SECTION 4.**

64 Said chapter is further amended by revising Code Section 16-13-59, relating to information  
 65 to include for each Schedule II, III, IV, or V controlled substance prescription and  
 66 compliance, as follows:

67 "16-13-59.

68 (a) For purposes of the program established pursuant to Code Section 16-13-57, each  
 69 dispenser shall submit to the agency department by electronic means information regarding  
 70 each prescription dispensed for a Schedule II, III, IV, or V controlled substance. The  
 71 information submitted for each prescription shall include at a minimum, but shall not be  
 72 limited to:

73 (1) DEA permit number or approved dispenser facility controlled substance  
 74 identification number;

75 (2) Date the prescription was dispensed;

76 (3) Prescription serial number;

77 (4) If the prescription is new or a refill;

78 (5) National Drug Code (NDC) for drug dispensed;

79 (6) Quantity and strength dispensed;

80 (7) Number of days supply of the drug;

81 (8) Patient's name;

82 (9) Patient's address;

83 (10) Patient's date of birth;

84 (11) Patient gender;

85 (12) Method of payment;

86 (13) Approved prescriber identification number or prescriber's DEA permit number;

87 (14) Date the prescription was issued by the prescriber; and

88 (15) Other data elements consistent with standards established by the American Society  
 89 for Automation in Pharmacy, if designated by regulations of the agency department.

90 (b) Each dispenser shall submit the prescription information required in subsection (a) of  
 91 this Code section in accordance with transmission methods and frequency requirements  
 92 established by the agency department ~~on at least a weekly basis and shall report, at a~~  
 93 ~~minimum, such prescription information no later than ten days after the prescription is~~  
 94 ~~dispensed.~~ If a dispenser is temporarily unable to comply with this subsection due to an

95 equipment failure or other circumstances, such dispenser shall notify the ~~board and agency~~  
 96 ~~the~~ department.

97 (c) The ~~agency~~ department may issue a waiver to a dispenser that is unable to submit  
 98 prescription information by electronic means acceptable to the ~~agency~~ department. Such  
 99 waiver may permit the dispenser to submit prescription information to the ~~agency~~  
 100 department by paper form or other means, provided all information required in subsection  
 101 (a) of this Code section is submitted in this alternative format and in accordance with the  
 102 frequency requirements established pursuant to subsection (b) of this Code section.  
 103 Requests for waivers shall be submitted in writing to the ~~agency~~ department.

104 (d) The ~~agency~~ department shall not revise the information required to be submitted by  
 105 dispensers pursuant to subsection (a) of this Code section more frequently than annually.  
 106 Any such change to the required information shall neither be effective nor applicable to  
 107 dispensers until six months after the adoption of such changes.

108 (e) The ~~agency~~ department shall not access or allow others to access any identifying  
 109 prescription information from the electronic data base after two years from the date such  
 110 information was originally received by the ~~agency~~ department. The ~~agency~~ department  
 111 may retain ~~aggregated de-identified~~ prescription information for a ~~period of two years from~~  
 112 ~~the date the information is received~~ more than two years but shall promulgate regulations  
 113 and procedures that will ensure that any identifying information the ~~agency~~ department  
 114 receives from any dispenser or reporting entity that is two years old or older is deleted or  
 115 destroyed on an ongoing basis in a timely and secure manner.

116 (f) A dispenser may apply to the ~~agency~~ department for an exemption to be excluded from  
 117 compliance with this Code section if compliance would impose an undue hardship on such  
 118 dispenser. The ~~agency~~ department shall provide guidelines and criteria for what constitutes  
 119 an undue hardship.

120 (g) For purposes of this Code section, the term 'dispenser' shall include any pharmacy or  
 121 facility physically located in another state or foreign country that in any manner ships,  
 122 mails, or delivers a dispensed controlled substance into this state."

## 123 **SECTION 5.**

124 Said chapter is further amended by revising Code Section 16-13-60, relating to privacy and  
 125 confidentiality, use of data, and security program, as follows:

126 "(a) Except as otherwise provided in subsections (c), (c.1), and (d) of this Code section,  
 127 prescription information submitted pursuant to Code Section 16-13-59 shall be confidential  
 128 and shall not be subject to open records requirements, as contained in Article 4 of  
 129 Chapter 18 of Title 50.

130 (b) The ~~agency~~ department, in conjunction with the board, shall establish and maintain  
131 strict procedures to ensure that the privacy and confidentiality of patients, prescribers, and  
132 patient and prescriber information collected, recorded, transmitted, and maintained  
133 pursuant to this part are protected. Such information shall not be disclosed to any person  
134 or entity except as specifically provided in this part and only in a manner which in no way  
135 conflicts with the requirements of the federal Health Insurance Portability and  
136 Accountability Act (HIPAA) of 1996, P.L. 104-191. Nothing in this subsection shall be  
137 construed to prohibit the agency from accessing prescription information as a part of an  
138 investigation into suspected or reported abuses or regarding illegal access of the data. Such  
139 information may be used in the prosecution of an offender who has illegally obtained  
140 prescription information.

141 (c) The ~~agency~~ department shall be authorized to provide requested prescription  
142 information collected pursuant to this part only as follows:

143 (1) To persons authorized to prescribe or dispense controlled substances for the sole  
144 purpose of providing medical or pharmaceutical care to a specific patient or to delegates  
145 of such persons authorized to prescribe or dispense controlled substances in accordance  
146 with the following:

147 (A) Such delegates are members of the prescriber or dispenser's staff and retrieve and  
148 review information and reports strictly for purposes of determining usage, misuse,  
149 abuse, or underutilization of prescribed medication;

150 (B) Such delegates are licensed, registered, or certified by the state regulatory board  
151 governing the delegating prescriber or dispenser, and the delegating prescriber or  
152 dispenser shall be held responsible for the use of the information and data by their  
153 delegates; and

154 (C) All information ~~and reports~~ retrieved and reviewed by delegates shall be  
155 maintained in a secure and confidential manner in accordance with the requirements of  
156 subsection (f) of this Code section;

157 (2) Upon the request of a patient, prescriber, or dispenser about whom the prescription  
158 information requested concerns or upon the request on his or her behalf of his or her  
159 attorney;

160 (3) To local or state law enforcement or prosecutorial officials pursuant to the issuance  
161 of a search warrant from an appropriate court or official in the county in which the office  
162 of such law enforcement or prosecutorial officials are located pursuant to Article 2 of  
163 Chapter 5 of Title 17 or to federal law enforcement or prosecutorial officials pursuant to  
164 the issuance of a search warrant pursuant to 21 U.S.C. or a grand jury subpoena pursuant  
165 to 18 U.S.C.; and

166 (4) To the agency, the Georgia Composite Medical Board or any other state regulatory  
 167 board governing prescribers or dispensers in this state, or the Department of Community  
 168 Health for purposes of the state Medicaid program, for health oversight purposes, or upon  
 169 the issuance of a subpoena by such agency, board, or department pursuant to their  
 170 existing subpoena power or to the federal Centers for Medicare and Medicaid Services  
 171 upon the issuance of a subpoena by the federal government pursuant to its existing  
 172 subpoena powers.

173 (c.1) An individual authorized to access electronic data base prescription information  
 174 pursuant to this part may:

175 (1) Communicate concerns about a patient's potential usage, misuse, abuse, or  
 176 underutilization of a controlled substance with ~~other~~ prescribers and dispensers that are  
 177 involved in the patient's health care; ~~or~~ and

178 (2) Report potential violations of this article to the agency for review or investigation.  
 179 Following such review or investigation, the agency ~~may~~ shall:

180 (A) Refer instances of a patient's possible personal misuse or abuse of controlled  
 181 substances to the patient's primary prescriber to allow for potential intervention and  
 182 impairment treatment;

183 (B) Refer probable violations of controlled substances being acquired for illegal  
 184 distribution, and not solely for a patient's personal use, to the appropriate authorities,  
 185 including the Georgia Bureau of Investigation, for further investigation and potential  
 186 prosecution; or

187 (C) Refer probable regulatory violations by prescribers or dispensers to the regulatory  
 188 board governing such person.

189 (d) The ~~board~~ department may provide ~~statistical~~ de-identified data to government entities  
 190 and other entities for statistical, research, educational, instructional, drug abuse prevention,  
 191 or grant application purposes after removing information that could be used to identify  
 192 prescribers ~~or individual patients or persons who received prescriptions from dispensers;~~  
 193 ~~the board may provide nonpatient specific data to the agency for instructional, drug abuse~~  
 194 ~~prevention, and research purposes.~~

195 (e) Any person or entity ~~who~~ that receives electronic data base prescription information  
 196 or related reports relating to this part from the ~~agency~~ department shall not ~~provide~~ disclose  
 197 such information or reports to any other person or entity except by order of a court of  
 198 competent jurisdiction or as otherwise permitted pursuant to this part.

199 (f) Any permissible user identified in this part who directly accesses electronic data base  
 200 prescription information shall implement and maintain a comprehensive information  
 201 security program that contains administrative, technical, and physical safeguards that are  
 202 substantially equivalent to the security measures of the ~~agency~~ department. The permissible

203 user shall identify reasonably foreseeable internal and external risks to the security,  
 204 confidentiality, and integrity of personal information that could result in the unauthorized  
 205 disclosure, misuse, or other compromise of the information and shall assess the sufficiency  
 206 of any safeguards in place to control the risks.

207 (g) No provision in this part shall be construed to modify, limit, diminish, or impliedly  
 208 repeal any authority ~~existing on June 30, 2011~~, of a licensing or regulatory board or any  
 209 other entity so authorized to obtain prescription information from sources other than the  
 210 data base maintained pursuant to this part; provided, however, that the agency department  
 211 shall be authorized to release information from the data base only in accordance with the  
 212 provisions of this part."

213

### SECTION 6.

214 Said chapter is further amended by revising Code Section 16-13-61, relating to the Electronic  
 215 Database Review Advisory Committee, members, terms, officers, procedure, and  
 216 compensation, as follows:

217 "16-13-61.

218 (a) There is established an Electronic Database Review Advisory Committee for the  
 219 purposes of consulting with and advising the agency department on matters related to the  
 220 establishment, maintenance, and operation of how prescriptions are electronically reviewed  
 221 pursuant to this part. This shall include, but shall not be limited to, data collection,  
 222 regulation of access to data, evaluation of data to identify benefits and outcomes of the  
 223 reviews, communication to prescribers and dispensers as to the intent of the reviews and  
 224 how to use the data base, and security of data collected.

225 (b) The advisory committee shall consist of ~~ten~~ eleven members as follows:

226 (1) A representative from the agency department;

227 (2) A representative from the Georgia Composite Medical Board;

228 (3) A representative from the Georgia Board of Dentistry;

229 (4) A representative with expertise in personal privacy matters, appointed by the  
 230 president of the State Bar of Georgia;

231 (5) A representative from a specialty profession that deals in addictive medicine,  
 232 appointed by the Georgia Composite Medical Board;

233 (6) A pain management specialist, appointed by the Georgia Composite Medical Board;

234 (7) An oncologist, appointed by the Georgia Composite Medical Board;

235 (8) A representative from a hospice or hospice organization, appointed by the Georgia  
 236 Composite Medical Board;

237 (9) A representative from the State Board of Optometry; ~~and~~

238 (10) The consumer member appointed by the Governor to the State Board of Pharmacy  
 239 pursuant to subsection (b) of Code Section 26-4-21-; and

240 (11) A representative from the agency.

241 (c) Each member of the advisory committee shall serve a three-year term or until the  
 242 appointment and qualification of such member's successor.

243 (d) The advisory committee shall elect a chairperson and vice chairperson from among its  
 244 membership to serve a term of one year. The vice chairperson shall serve as the  
 245 chairperson at times when the chairperson is absent.

246 (e) The advisory committee shall meet at the call of the chairperson or upon request by at  
 247 least three of the members and shall meet at least one time per year. Five members of the  
 248 committee shall constitute a quorum.

249 (f) The members shall receive no compensation or reimbursement of expenses from the  
 250 state for their services as members of the advisory committee."

251 **SECTION 7.**

252 Said chapter is further amended by revising Code Section 16-13-62, relating to rules and  
 253 regulations, as follows:

254 "16-13-62.

255 The agency department shall establish rules and regulations to implement the requirements  
 256 of this part. Nothing in this part shall be construed to authorize the agency department to  
 257 establish policies, rules, or regulations which limit, revise, or expand or purport to limit,  
 258 revise, or expand any prescription or dispensing authority of any prescriber or dispenser  
 259 subject to this part. Nothing in this part shall be construed to impede, impair, or limit a  
 260 prescriber from prescribing pain medication in accordance with the pain management  
 261 guidelines developed and adopted by the Georgia Composite Medical Board."

262 **SECTION 8.**

263 Said chapter is further amended in Code Section 16-13-64, relating to violations, criminal  
 264 penalties, and civil damages, by revising subsection (a) as follows:

265 "(a) A dispenser who knowingly and intentionally fails to submit prescription information  
 266 to the agency department as required by this part or knowingly and intentionally submits  
 267 incorrect prescription information shall be guilty of a felony and, upon conviction thereof,  
 268 shall be punished for each such offense by imprisonment for not less than one year nor  
 269 more than five years, a fine not to exceed \$50,000.00, or both, and such actions shall be  
 270 reported to the licensing board responsible for issuing such dispenser's dispensing license  
 271 for action to be taken against such dispenser's license."



272 **SECTION 9.**

273 Article 1 of Chapter 2A of Title 31, relating to the Department of Public Health, is amended  
 274 in Code Section 31-2A-4, relating to the obligation to safeguard and promote health of  
 275 people of the state, by revising paragraphs (13) and (14) and adding a new paragraph to read  
 276 as follows:

277 "(13) Exchange data with the Department of Community Health for purposes of health  
 278 improvement and fraud prevention for programs operated by the Department of  
 279 Community Health pursuant to mutually agreed upon data sharing agreements and in  
 280 accordance with federal confidentiality laws relating to health care; ~~and~~

281 (14) Provide The Council of Superior Court Clerks of Georgia the data set forth in Code  
 282 Section 15-12-40.1, without charge and in the electronic format requested: and

283 (15) Maintain and administer the electronic data base of prescription information  
 284 established under Code Section 16-13-57."

285 **SECTION 10.**

286 Article 9 of Chapter 7 of Title 31 of the Official Code of Georgia Annotated, relating to  
 287 hospice care, is amended by adding a new Code section to read as follows:

288 "31-7-180.

289 (a) As used in this Code section, the term 'controlled substance' means a drug, substance,  
 290 or immediate precursor in Schedules I through V of Code Sections 16-13-25  
 291 through 16-13-29.

292 (b) When a person dies while lawfully in possession of a controlled substance for personal  
 293 use, any person lawfully entitled to dispose of the decedent's property may deliver the  
 294 controlled substance to another person for the purpose of disposal under the same  
 295 conditions as provided for ultimate users pursuant to 21 U.S.C. 822(g) (4). An ultimate  
 296 user includes a person who has lawfully obtained and possesses a controlled substance for  
 297 his or her own use or for use by a member of his or her household pursuant  
 298 to 21 U.S.C. 802(27). A member of the hospice patient family unit or the hospice care team  
 299 as such terms are defined in this article shall be authorized to dispose of the deceased  
 300 patient's controlled substances under this Code section. Such controlled substances shall  
 301 be disposed of in accordance with the federal Controlled Substances Act. Such disposal  
 302 shall be conducted within 72 hours of the death of the patient."

303 **SECTION 11.**

304 All laws and parts of laws in conflict with this Act are repealed.